ライフサイエンスコーパス: drug action

1 s is critical to understanding mechanisms of drug action.

2 and lead to the understanding of disease and drug action.

3 deo-tracking analyses in zebrafish models of drug action.

4 toward novel signaling pathways involved in drug action.

5 intracellular digestive vacuole, the site of drug action.

6 or cells and to further define mechanisms of drug action.

7 that function to facilitate antitrypanosomal drug action.

8 ecular mechanisms enabling antihyperglycemic drug action.

9 nd links more than fifty additional genes to drug action.

10 AD may be an important aspect of antimitotic drug action.

11 l systems biology is empowering the study of drug action.

12 developed structural basis for understanding drug action.

13 or cells in select anatomical locations from drug action.

14 the Family B calcitonin receptor for agonist drug action.

15 ally providing a highly selective target for drug action.

16 drug and is independent of the mechanism of drug action.

17 itutions and the sponsor or the mechanism of drug action.

18 lar interface between gene transcription and drug action.

19 hologs, implying its intimate involvement in drug action.

20 l role for S-nitrosylation in antineoplastic drug action.

21 se to the drug or be potential biomarkers of drug action.

22 considered a required catalytic process for drug action.

23 of epileptic propagation and anti-epileptic drug action.

24 l biosynthesis that accumulates as result of drug action.

25 ent models of neuropsychiatric conditions or drug action.

26 ptors (GPCRs) are the most common targets of drug action.

27 oltage-gated K(+) channels are refractory to drug action.

28 icacy as well as for real-time monitoring of drug action.

29 artly underlies the antianginal mechanism of drug action.

30 amics, which represent potential targets for drug action.

31 Clearance is the practical limit on drug action.

32 for channel gene expression in this delayed drug action.

33 information about the cellular physiology of drug action.

34 s an intracellular site for antiinflammatory drug action.

35 he introduction of an intracellular delay in drug action.

36 ontrol provides the safest means to regulate drug action.

37 on and thus a potential target for antiviral drug action.

38 new mechanism to account for this change in drug action.

39 aryl hydrocarbon receptor (AhR) may mediate drug action.

40 fore, this study characterized the basis for drug action.

41 dynamics and hence are promising targets for drug action.

42 hysiology of schizophrenia and antipsychotic drug action.

43 presents a novel mechanism of antiarrhythmic drug action.

44 neural mechanisms of atypical antipsychotic drug action.

45 y be an essential part of the antidepressant drug action.

46 activation gating and class I antiarrhythmic drug action.

47 binding sites are among the major targets of drug action.

48 utically desirable property of use-dependent drug action.

49 to doxorubicin, implicating these regions in drug action.

50 laque ACE probably is an important target of drug action.

51 rowth and is a potential site for anticancer drug action.

52 drug discovery by enabling pathway-selective drug action.

53 udying and optimizing TEC-driven biology and drug action.

54 le organization with direct implications for drug action.

55 blishing respective confirmatory pathways of drug action.

56 ve essential roles in psilocybin's long-term drug action.

57 nciples of neuromodulation and mechanisms of drug action.

58 t peptide that otherwise is conducive to the drug action.

59 her define critical neuroanatomic targets of drug action.

60 tter understanding of the molecular basis of drug action.

61 as the contribution of signal propagation to drug action.

62 iver injury and to identify the mechanism of drug action.

63 estigating metabolism, genome stability, and drug action.

64 ssociated with depression and antidepressant drug action.

65 y enabling light-mediated spatial control of drug action.

66 idance conflict tests in terms of anxiolytic drug action.

67 urate models of the kinetics and dynamics of drug action.

68 lues, consistent with a bimodal mechanism of drug action.

69 ical proteomics for discerning mechanisms of drug action.

70 bility and metabolic stability necessary for drug action.

71 ic physiological mechanisms of the treatment drug action.

72 unds, demonstrating that CA is the target of drug action.

73 nal classes and frequently occur at sites of drug action.

74 lopment but also to understand mechanisms of drug action.

75 approach to uncover molecular mechanisms of drug action.

76 ucidating genetic networks and mechanisms of drug action.

77 l drugs and propose respective mechanisms of drug action.

78 novel drug targets and deep understanding of drug action.

79 uptake and trafficking, and the mechanism of drug action.

80 simple inhibition and complex mechanisms of drug action.

81 molecule are among the most fundamental for drug action.

82 ells could provide a better understanding of drug action.

83 often provide an incomplete understanding of drug action.

84 enetic changes that may impact antipsychotic drug action.

85 an analytical model for the verification of drug action.

86 l interactions, barrier control function and drug action.

87 oside analogues for anticancer and antiviral drug actions.

88 drug(s), such as the molecular mechanisms of drug actions.

89 ientific discoveries about the mechanisms of drug actions.

90 t spatiotemporal Ca2+ patterns contribute to drug actions.

91 pproaches match this precision to understand drug actions.

92 s in neural circuit function and therapeutic drug actions.

93 ncer metabolism and its use in understanding drug actions.

94 essential to accurately quantify agonist and drug actions.

95 n nociception, analgesia, and antidepressant drug actions.

96 essential to accurately quantify agonist and drug actions.

97 Owing to the complexity of drug actions, a broader genomics approach aims at findin

98 asy and less invasive application, sustained drug action, ability to tailor drug delivery, reduction

99 le the intended and unintended mechanisms of drug action across diverse essential cellular processes.

100 s, it is critical to understand the basis of drug action against M. tuberculosis gyrase and how mutat

101 (+)-channel blocking (class I antiarrhythmic drug) action, along with mathematical models of canine a

102 eceptor endocytosis in the biology of opiate drug action and addiction.

103 ral bases of receptor activation, signaling, drug action and allosteric modulation, but so far cover

104 This results in prolonged drug action and allows for reduction of drug doses requi

105 mathematical models to study the kinetics of drug action and decay within vertebrate hosts has a long

106 n healthy human hematopoiesis, against which drug action and disease can be compared for mechanistic

107 l in understanding the relationships between drug action and disease susceptibility genes.

108 biased agonism as a significant mechanism of drug action and do so in CNS-derived neurons expressing

109 ional screens to uncover novel mechanisms of drug action and document the role of the integrated stre

110 to encode rich information on mechanisms of drug action and drug resistance.

111 rich, detailed information on mechanisms of drug action and drug resistance.

112 s for new drugs, determining the duration of drug action and examining potential drug interactions.

113 ul for understanding molecular mechanisms of drug action and for identifying protein targets that may

114 nd enhance the utility of yeast for studying drug action and for mechanism-based drug discovery.

115 tissues to provide mechanistic insights into drug action and for the purpose of identifying candidate

116 a reveal a novel mechanism of antiarrhythmic drug action and highlight the possibility for new agents

117 Despite its importance for drug action and in revealing potential sites of topoisom

118 However, the mechanism of drug action and its effect on FtsZ in other bacterial sp

119 linkage between a loss of fitness caused by drug action and Mtb's sensitivity to host-derived stress

120 ramework for understanding the mechanisms of drug action and parasite resistance.

121 l facilitate understanding the mechanisms of drug action and possible side effects.

122 ein-drug interactions illuminate the mode of drug action and provide a framework for rational design

123 h on dopamine as a mediator of antipsychotic drug action and putative roles for this transmitter in t

124 a better understanding of the mechanisms of drug action and resistance are essential for fulfilling

125 nogalactan, but the molecular mechanisms for drug action and resistance are unknown.

126 standing the mechanisms underlying selective drug action and resistance for the development of improv

127 rium cells has implications in understanding drug action and resistance mechanisms.

128 One of the mechanisms of drug action and resistance of 5-FU is through DNA incorp

129 Knowledge of the mechanisms of drug action and resistance was stressed to be essential

130 To better assess drug action and resistance, we sequenced the genomes of

131 be necessary to understand the mechanisms of drug action and resistance.

132 ata; (c) providing insights on mechanisms of drug action and resistance; and (d) generating leads for

133 rovide useful fingerprints for mechanisms of drug action and response.

134 vant, drug-resistant mutants must both evade drug action and retain pathogenicity.

135 um glucose for galactose sensitized cells to drug action and revealed novel response parameters.

136 roaches, we identify SOD as a target of this drug action and show that chemical modifications at the

137 ns remain as to the exact mechanisms of both drug action and side-effect profile, nevertheless it is

138 atment likely reflect the different modes of drug action and sites of infection for these two helmint

139 y MAPK pathway-mutant cancers rapidly escape drug action and that suppressing early stress tolerance

140 information to understand the mechanisms of drug action and the functional structures of biomolecule

141 of MorphEUS to rapidly identify pathways of drug action and the proximal cause of cellular damage in

142 om getting to its protein target, that mimic drug action and thereby partially alleviate drug craving

143 Antiarrhythmic drug actions and electrophysiological characteristics of

144 By considering drug actions and side effects in the context of the regu

145 -signaling pathways to understand unintended drug actions and to facilitate drug discovery and screen

146 between mechanistic and operational modes of drug action, and allows operational parameters to be giv

147 g from the inhibition of a protein through a drug action, and demonstrate how this approach can be us

148 ach to the development of models of disease, drug action, and drug toxicity.

149 aging of cell migration, signaling pathways, drug action, and interacting protein partners in vivo al

150 tions for parasite development, antimalarial drug action, and mechanisms of drug resistance.

151 g, protein association, protein degradation, drug action, and second messengers in real time.

152 o bridge specific biomarkers to mechanism of drug action, and specific clinical outcomes.

153 iality, discover leads for gene function and drug action, and understand higher-order organization of

154 tive-state tissue signaling biology, complex drug actions, and dysfunctional signaling in diseased ce

155 mic medications with germline sensitivity to drug actions, and might identify ALL patients at highest

156 oviding a profile in which changes caused by drug action are directly observed.

157 ential reactivation rates and differences in drug action are not known.

158 tient-to-patient variability and independent drug action are sufficient to explain the superiority of

159 ons, although proper frameworks to represent drug actions are still lacking.

160 rmacology which utilizes network analysis of drug action as one of its approaches.

161 nia (SCZ) both as a target for antipsychotic drug action as well as a SCZ-associated risk gene.

162 ly useful to cast light on the mechanisms of drug action as well as to monitor the treatment of depre

163 y information on the structural dynamics and drug action at metabotropic glutamate receptors and vali

164 rived modelling improve our understanding of drug action at single-cell resolution in vivo.

165 sults provide novel mechanistic insight into drug action at single-cell resolution.

166 and toward delineating the cellular basis of drug action at the level of defined GPCR interaction net

167 sights into the molecular level mechanism of drug action at the membrane site, we have carried out ex

168 eptor antagonist, SCH 23390, consistent with drug actions at D1 receptors.

169 ere is considerable evidence to suggest that drug actions at the kappa-opioid receptor (KOR) may repr

170 ential mechanisms of use- or state-dependent drug action based on activation gating, or slower pore-b

171 may have implications for the selectivity of drug actions based on the subcellular distribution of th

172 and the cerebral cortex in acute psychedelic drug action, but different models have evolved to try to

173 metabolic flux is critical for understanding drug action, but traditional isotope kinetic assays face

174 light to control the location and timing of drug action by incorporating a photoisomerizable azobenz

175 reuptake inhibitors (SSRIs), initiate their drug actions by rapid elevation of serotonin, but they t

176 also suggests that this unique mechanism of drug action can be further exploited to develop strategi

177 This drug action can be observed with native cells, such as H

178 Understanding the molecular basis of drug action can facilitate development of more potent an

179 Control experiments indicated that these drug actions could be attributed to local and not system

180 he damage in the coronal pulp tissue with no drug action detected in the root pulp.

181 ling pathways to facilitate understanding of drug action, disease pathogenesis, and identification of

182 signaling, metabolic and regulatory pathway, drug action, disease susceptibility, and organ specifici

183 dria or liposomes, indicating a mechanism of drug action downstream from this event.

184 In a combination exhibiting independent drug action, each patient benefits solely from the drug

185 e progression and outcomes; TB transmission; drug action, efficacy and drug resistance.

186 ations in interpretation of the mechanism of drug actions, especially when the drugs are given togeth

187 The dominant paradigm in understanding drug action focuses on the intended therapeutic effects

188 s, and suggest possible molecular markers of drug action for use in hypothesis testing clinical trial

189 tiple occasions, and a proposed mechanism of drug action had previously been assigned to each agent.

190 ponicum The reason for this species-specific drug action has remained a mystery for decades.

191 anisms governing neurotransmitter uptake and drug action have moved into high gear with the publicati

192 suggest a novel mechanism of antidepressant drug action having a delayed onset.

193 s may derive their efficacy from independent drug action (IDA), where patients only receive benefit f

194 Our single-cell analysis of drug action illustrates the strength of quantitative app

195 cs, they directly represent probabilities of drug action in a cell population.

196 an impact on our understanding of antibiotic drug action in bacteria.

197 bitors revealed a high degree of synergistic drug action in combination with the clinical leukemia th

198 gy could be adapted to predict mechanisms of drug action in complex biological systems.

199 A break implies that there are two sites for drug action in every enzyme-DNA cleavage complex.

200 a systematic understanding of small-molecule drug action in genetically distinct individuals.

201 s important determinants of polyamine analog drug action in melanoma cells.

202 Human and animal studies of psychedelic drug action in the brain have demonstrated the involveme

203 or calcineurin B in virulence and antifungal drug action in the human fungal pathogen C. neoformans.

204 u receptor agonists to reduce hallucinogenic drug action in this region is believed to be directly re

205 se accessibility to amino acids critical for drug action in TM1, TM2, and TM3, which may provide a me

206 te regarding incretin receptors and incretin drug actions in the PNS, as well as PNS control over inc

207 ew questions about the fundamental nature of drug actions in vivo.

208 del for isolating SERT/5-HT contributions of drug actions in vivo.

209 pproaches to understanding of antidepressant drug action include a focus on early changes in emotiona

210 ly stimulates many surrogates of psychedelic drug actions including head twitches, grooming, retrogra

211 mechanisms to account for the slow onset of drug action, including drug accumulation and structural

212 e data elucidate a novel basis for antitumor drug action: induction in sensitive cells of a metaboliz

213 Drug action involved Drk1 cysteine 392, as a C392S subst

214 Bu-induced reactivation of HSV-1 is twofold: drug action involving significant moderation of specific

215 The mechanism of drug action is a combination of remodeling of the gliobl

216 cule colon-selective therapies for localized drug action is an attractive strategy in treating coloni

217 smitter-based explanation for antidepressant drug action is challenged by the delayed clinical onset

218 Currently, drug action is determined with a fluorimetric/colorimetr

219 An early event in drug action is the direct targeting of mitochondria by r

220 , the role of HERG inactivation in class III drug action is uncertain: pore mutations that remove ina

221 involvement in resilience and antidepressant drug action, is a common genetic locus of risk for menta

222 skin rash may be a pharmacodynamic marker of drug action, its potential as a surrogate marker of clin

223 were subsequently evaluated to elucidate the drug action mechanism in vivo.

224 This finding unveils a novel drug-action mechanism where the binding of INHs to Hec1

225 SC-CM populations and to predict and explain drug action mechanisms.

226 cortex are secondary to this primary site of drug action, mediated through classically described stri

227 tween p19 inhibitors suggest that individual drug action might be modulated by antibody affinity.

228 rrent pulses to determine the time course of drug action (n=85 cells) and with prototypical taste sti

229 behaving animals and link them to anxiolytic drug action, novelty, and the metric for self-motion.

230 an give valuable insights into mechanisms of drug action, off target pharmacology and toxicity.

231 Additionally, the specificity of the drug action on A20 was confirmed using cell lines with t

232 ry cells and can report pharmacodynamics for drug action on an intended target, this methodology coul

233 urons for studying the mechanisms of triptan drug action on CGRP synthesis.

234 e the assessment of dose- and time-dependent drug action on gametocyte maturation and transmission.

235 re is a lack of mechanistic insights into Pf drug action on inflammatory cells such as neutrophils.

236 th anti-depressant, antipsychotic and opioid drug action on primary human neurons in vitro.

237 In order to achieve selectivity in drug action on the CXCR4/CXCL12 pair, in particular in t

238 ction, as a tool to anticipate the effect of drug action on the same target.

239 ting DreamLab platform) was used to simulate drug actions on human interactome networks to obtain gen

240 ill slopes, suggesting that the isoboles for drug actions on ion channel function are not linear.

241 red together for a complete understanding of drug actions on ligand-gated ion channels.

242 It was of interest to determine drug actions on these receptors, and we investigated the

243 However, drug actions on these systems are not necessarily the sa

244 e antitumor response was triggered by direct drug actions on tumor cells, relied on innate immune sen

245 ication period is divided into pre- and post-drug action parts, allowing for the introduction of an i

246 tanding how specific genetic variants modify drug action pathways may provide informative blueprints

247 interactions may unravel previously unknown drug action patterns, leading to the development of new

248 e drug concentrations (pharmacokinetics) and drug actions (pharmacodynamics), available data from cli

249 creens link ubiquinone availability to nitro-drug action, plasma membrane P-type H(+)-ATPases to pent

250 This mechanism of drug action potently removes SAP from human amyloid depo

251 An understanding of the molecular basis of drug action provides opportunities for refinement of dru

252 However, the mechanism of the drug action remain a conjecture.

253 The target tissues of drug actions remain unclear.

254 act of this environment on antimycobacterial drug action remains incomplete.

255 Drug action requires the presence of a group III hybrid

256 l peptidyltransferase as the primary site of drug action, some biochemical studies conducted in vitro

257 structures raises mechanistic hypotheses on drug action, suggesting that VX-770 might allow an open-

258 into the spatial and temporal specificity of drug action that can be provided by allosteric modulatio

259 nd could provide an alternative mechanism of drug action that can explain its clinical activity.

260 ysosome as a potential new site of CGP-48664 drug action that could be involved in antitumor activity

261 noclustering, revealing a novel mechanism of drug action that has important consequences for cell sig

262 provide novel insight into the mechanism of drug action that influence treatment outcome: drug sensi

263 anism of pol II transcription inhibition and drug action that is dramatically different from transcri

264 quires an integrative modeling framework for drug action that leverages advances in data-driven stati

265 Our results provide principles of drug action that may facilitate future design of small m

266 In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent i

267 activity measured directly in the target of drug action, the leukemic cell.

268 d in livestock, the possible mechanism(s) of drug action, the proposed mechanisms and genetic basis o

269 nformation available regarding mechanisms of drug action, the relative significance of downstream eve

270 general mechanisms underlying variability in drug action, the role of genetic variation in mediating

271 pharmacokinetic/pharmacodynamic analyses of drug action; the two approaches gave consistent results.

272 standing of the biologic bases of cancer and drug action, thereby improving diagnosis and treatment,

273 egarding the molecular mechanisms underlying drug action, these approaches are often inefficient, low

274 ng of the mechanisms of complex diseases and drug actions through network analysis, novel drug method

275 typic response to the molecular mechanism of drug action, thus offering a unique pathway-centric stra

276 ling in a manner relevant to psychostimulant drug actions, thus inviting evaluation of psychostimulan

277 h used in systems pharmacology can allow for drug action to be considered in the context of the whole

278 gments are central to processes ranging from drug action to selective catalysis.

279 To understand drug action today, we characterize the targets through w

280 that a detailed mechanistic understanding of drug action, together with careful selection of disease

281 Assays of drug action typically evaluate biochemical activity.

282 n optical imaging approaches that put opioid drug action "under the microscope." SIGNIFICANCE STATEME

283 However, mechanisms of drug action underlying side effect pathogenesis remain l

284 Characterization of drug action using a transposon library bioinformatic pla

285 Compartment-specific drug action was indeed observed.

286 The next step for polymeric drug action was inhibition of tumor angiogenesis by spec

287 insight into the potential mechanisms of ART drug action, we developed a suite of ART activity-based

288 mine whether RhoB-GG has a necessary role in drug action, we examined the FTI response of murine fibr

289 his knowledge and the rapid reversibility of drug action, we examined the restoration of rod shape in

290 ns among diseases, genetic perturbation, and drug action, we have created the first installment of a

291 ic, epigenetic, and environmental factors on drug action, we must study the structural energetics and

292 PITX2-dependent mechanisms of antiarrhythmic drug action were studied in human embryonic kidney (HEK)

293 icacy, two of the most important features of drug action, which represent the latest chapter in the s

294 tabolic response to molecular expression and drug action, which would greatly accelerate drug develop

295 may limit opportunities to grasp unintended drug actions, which can open up channels to repurpose ex

296 standing the molecular mechanisms underlying drug action while addressing some very practical questio

297 (Mw) fucoidan can limit its effectiveness in drug action, while lower Mw fractions exhibit increased

298 Testing these potential mechanisms of drug action will facilitate rational improvement of anti

299 ramework for understanding gene function and drug action within the context of energy metabolism.

300 that a detailed molecular analysis of opiate drug actions would someday lead to better treatments for